173 related articles for article (PubMed ID: 9489820)
1. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.
van Vollenhoven RF; Morabito LM; Engleman EG; McGuire JL
J Rheumatol; 1998 Feb; 25(2):285-9. PubMed ID: 9489820
[TBL] [Abstract][Full Text] [Related]
2. Dehydroepiandrosterone in systemic lupus erythematosus: relationship between dosage, serum levels, and clinical response.
Barry NN; McGuire JL; van Vollenhoven RF
J Rheumatol; 1998 Dec; 25(12):2352-6. PubMed ID: 9858429
[TBL] [Abstract][Full Text] [Related]
3. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial.
Chang DM; Lan JL; Lin HY; Luo SF
Arthritis Rheum; 2002 Nov; 46(11):2924-7. PubMed ID: 12428233
[TBL] [Abstract][Full Text] [Related]
4. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.
Petri MA; Lahita RG; Van Vollenhoven RF; Merrill JT; Schiff M; Ginzler EM; Strand V; Kunz A; Gorelick KJ; Schwartz KE;
Arthritis Rheum; 2002 Jul; 46(7):1820-9. PubMed ID: 12124866
[TBL] [Abstract][Full Text] [Related]
5. Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus.
Nordmark G; Bengtsson C; Larsson A; Karlsson FA; Sturfelt G; Rönnblom L
Autoimmunity; 2005 Nov; 38(7):531-40. PubMed ID: 16373258
[TBL] [Abstract][Full Text] [Related]
6. Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial.
Hartkamp A; Geenen R; Godaert GL; Bijl M; Bijlsma JW; Derksen RH
Ann Rheum Dis; 2010 Jun; 69(6):1144-7. PubMed ID: 19854713
[TBL] [Abstract][Full Text] [Related]
7. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
Petri MA; Mease PJ; Merrill JT; Lahita RG; Iannini MJ; Yocum DE; Ginzler EM; Katz RS; Gluck OS; Genovese MC; Van Vollenhoven R; Kalunian KC; Manzi S; Greenwald MW; Buyon JP; Olsen NJ; Schiff MH; Kavanaugh AF; Caldwell JR; Ramsey-Goldman R; St Clair EW; Goldman AL; Egan RM; Polisson RP; Moder KG; Rothfield NF; Spencer RT; Hobbs K; Fessler BJ; Calabrese LH; Moreland LW; Cohen SB; Quarles BJ; Strand V; Gurwith M; Schwartz KE
Arthritis Rheum; 2004 Sep; 50(9):2858-68. PubMed ID: 15452837
[TBL] [Abstract][Full Text] [Related]
8. Studies of dehydroepiandrosterone (DHEA) as a therapeutic agent in systemic lupus erythematosus.
Van Vollenhoven RF; McGuire JL
Ann Med Interne (Paris); 1996; 147(4):290-6. PubMed ID: 8952750
[TBL] [Abstract][Full Text] [Related]
9. Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus.
Chang DM; Chu SJ; Chen HC; Kuo SY; Lai JH
Ann Rheum Dis; 2004 Dec; 63(12):1623-6. PubMed ID: 15547086
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of pregnenolone and 17-hydroxypregnenolone in patients with rheumatoid arthritis and systemic lupus erythematosus: relation to other adrenal hormones.
Vogl D; Falk W; Dorner M; Schölmerich J; Straub RH
J Rheumatol; 2003 Feb; 30(2):269-75. PubMed ID: 12563679
[TBL] [Abstract][Full Text] [Related]
11. The effect of menopause on disease activity in systemic lupus erythematosus.
Urowitz MB; Ibañez D; Jerome D; Gladman DD
J Rheumatol; 2006 Nov; 33(11):2192-8. PubMed ID: 16981295
[TBL] [Abstract][Full Text] [Related]
12. Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy.
Sánchez-Guerrero J; Fragoso-Loyo HE; Neuwelt CM; Wallace DJ; Ginzler EM; Sherrer YR; McIlwain HH; Freeman PG; Aranow C; Petri MA; Deodhar AA; Blanton E; Manzi S; Kavanaugh A; Lisse JR; Ramsey-Goldman R; McKay JD; Kivitz AJ; Mease PJ; Winkler AE; Kahl LE; Lee AH; Furie RA; Strand CV; Lou L; Ahmed M; Quarles B; Schwartz KE
J Rheumatol; 2008 Aug; 35(8):1567-75. PubMed ID: 18634158
[TBL] [Abstract][Full Text] [Related]
13. The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus.
Hartkamp A; Geenen R; Godaert GL; Bijl M; Bijlsma JW; Derksen RH
Arthritis Rheum; 2004 Nov; 50(11):3591-5. PubMed ID: 15529389
[TBL] [Abstract][Full Text] [Related]
14. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus.
Carneiro JR; Sato EI
J Rheumatol; 1999 Jun; 26(6):1275-9. PubMed ID: 10381042
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia.
Finckh A; Berner IC; Aubry-Rozier B; So AK
J Rheumatol; 2005 Jul; 32(7):1336-40. PubMed ID: 15996074
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus.
van Vollenhoven RF; Park JL; Genovese MC; West JP; McGuire JL
Lupus; 1999; 8(3):181-7. PubMed ID: 10342710
[TBL] [Abstract][Full Text] [Related]
17. Hormones and lupus: defective dehydroepiandrosterone activity induces impaired interleukin-2 activity of T lymphocytes in patients with systemic lupus erythematosus.
Suzuki N; Suzuki T; Sakane T
Ann Med Interne (Paris); 1996; 147(4):248-52. PubMed ID: 8952743
[TBL] [Abstract][Full Text] [Related]
18. Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus.
Gordon C; Wallace DJ; Shinada S; Kalunian KC; Forbess L; Braunstein GD; Weisman MH
Rheumatology (Oxford); 2008 Mar; 47(3):334-8. PubMed ID: 18238794
[TBL] [Abstract][Full Text] [Related]
19. Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy.
Mease PJ; Ginzler EM; Gluck OS; Schiff M; Goldman A; Greenwald M; Cohen S; Egan R; Quarles BJ; Schwartz KE
J Rheumatol; 2005 Apr; 32(4):616-21. PubMed ID: 15801015
[TBL] [Abstract][Full Text] [Related]
20. Long-term low-dose oral administration of dehydroepiandrosterone modulates adrenal response to adrenocorticotropic hormone in early and late postmenopausal women.
Genazzani AR; Pluchino N; Begliuomini S; Stomati M; Bernardi F; Pieri M; Casarosa E; Palumbo M; Genazzani AD; Luisi M
Gynecol Endocrinol; 2006 Nov; 22(11):627-35. PubMed ID: 17145649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
